Navigation Links
Merrimack Pharmaceuticals Initiates Enrollment in Phase 1/2 Combination Study of MM-121 and Tarceva in Patients with Non-Small Cell Lung Cancer
Date:2/22/2010

MM-121, Merrimack’s lead oncology therapeutic candidate, is an antibody designed to block signaling of ErbB3. This is the first of multiple trials that Merrimack and sanofi-aventis expect to initiate in 2010 as part of a broad Phase 2 clinical development program for MM-121.

Cambridge, Mass. (PRWEB) February 22, 2010 -- Merrimack Pharmaceuticals, Inc. announced today that the first patient has received an initial dose in a Phase 1/2 clinical study combining MM-121 with Tarceva® (erlotinib) in patients with non-small cell lung cancer (NSCLC). This is the first of multiple trials that Merrimack and sanofi-aventis expect to initiate in 2010 as part of a broad Phase 2 clinical development program for MM-121.

MM-121, Merrimack’s lead oncology therapeutic candidate, is an antibody designed to block signaling of ErbB3. Erlotinib is a small molecule targeting the epidermal growth factor receptor (EGFR).

“Our Network Biology analysis of cancer cells indicates that tumors often become resistant to EGFR-targeted therapies by compensating for tumor growth restriction through the ErbB3 receptor,” stated Clet Niyikiza, Ph.D., Senior Vice President of Development at Merrimack. “We believe that this discovery, which has since been confirmed by leading academic laboratories, indicates that MM-121 in combination with Tarceva® could be a powerful treatment for lung cancer patients who no longer respond to EGFR treatment alone.”

The Phase 1/2 study will initially evaluate the human safety and pharmacokinetics (PK) of MM-121 in combination with erlotinib, establish a safe combination regimen, and then inve
'/>"/>

Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved  

Page: 1 2 3

Related biology technology :

1. Merrimack Pharmaceuticals Announces the Addition of Robert Gay to its Board of Directors
2. Merrimack Pharmaceuticals Raises $60 Million in Private Financing
3. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist
4. Merrimack Pharmaceuticals Promotes Ulrik B. Nielsen, Ph.D. to Chief Scientific Officer and Edward J. Stewart to Senior Vice President of Business Development
5. Merrimack Pharmaceuticals Names Clet Niyikiza, Ph.D. Senior Vice President, Development
6. Merrimack Pharmaceuticals Acquires Hermes Biosciences, Inc.
7. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
8. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
9. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
10. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
11. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Merrimack Pharmaceuticals Initiates Enrollment in Phase 1/2 Combination Study of MM-121 and Tarceva in Patients with Non-Small Cell Lung Cancer
(Date:8/1/2014)... 01, 2014 Chantel Lee ’15 and Eli ... 10 40-hour weeks with Dr. Juan Rodriguez, Professor of Physics, ... a common diabetic eye disease caused by changes in the ... and Eli accomplished is quite remarkable,” said Rodriguez. “They took ... when they started, and together carried it to near completion ...
(Date:8/1/2014)... CHICAGO , Aug. 1. 2014 As ... U.S., the 2014 AACC Annual Meeting & Clinical Lab ... testing and patient care are introduced to the healthcare ... by the Expo,s 650 exhibitors will include the latest ... Advances in smartphones and biosensors have enabled ...
(Date:8/1/2014)... Research and Markets has announced ... (SNP) Genotyping and Analysis Market 2014-2018" report to ... Single Nucleotide Polymorphism (SNP) genotyping is the ... the genome of various species. SNPs are commonly present ... technology can analyze thousands of SNPs and has the ...
(Date:8/1/2014)... (PRWEB) August 01, 2014 Testing ... led to a better understanding embryonic development. ... reorganize into structurally and functionally distinct tissues is ... defects. Prof. Todd McDevitt, Melissa Kinney, and ... signals interact with biochemical cues to control many ...
Breaking Biology Technology:Two Centenary College Students Tackle Diabetic Retinopathy Research 2Lab-on-a-Chip Technology to Be Featured at 2014 AACC Annual Meeting & Clinical Lab Expo 2Lab-on-a-Chip Technology to Be Featured at 2014 AACC Annual Meeting & Clinical Lab Expo 3Global Single Nucleotide Polymorphism (SNP) Genotyping and Analysis Market 2014-2018 2Study Links Biomechanics and Gene Expression in Stem Cells 2
... Forest Laboratories, Inc.,(NYSE: FRX ) and H. ... Court,of Appeals for the Federal Circuit has affirmed a ... the District of Delaware which determined that,the U.S. patent ... upheld the injunction preventing Ivax/Teva,s proposed generic,product launch, thereby ...
... a Proven Leader at Driving Growth, SAN FRANCISCO, ... equity firm that focuses on investments in selected segments,of ... software, today announced the appointment of Michael L. Hurt,to ... Mr. Hurt, CEO,of Altra Industrial Motion (Nasdaq: AIMC ...
... Diagnostic Systems Installs CTLM(R) in Tianjin, China, ... Inc., (OTC Bulletin Board: IMDS) a pioneer in ... CT Laser Mammography,(CTLM(R)) system at the Tianjin Medical ... center in China. (Logo: http://www.newscom.com/cgi-bin/prnh/20040412/IMDSLOGO ...
Cached Biology Technology:Forest Laboratories Announces Federal Appeals Court Upholds Lexapro(R) Patent Decision 2Genstar Names Michael Hurt to Its Strategic Advisory Board 2Largest Asian Cancer Hospital to Evaluate New CT Laser Breast Imaging System 2Largest Asian Cancer Hospital to Evaluate New CT Laser Breast Imaging System 3
(Date:8/1/2014)... research will provide enormous opportunities for both biological ... replicate any other cells in the body, offering ... spinal cords, treating kidney, liver and lung diseases ... profit is staggering. Prof. Jinhui Chen from Indiana ... research still faces myriad biological, ethical, legal, political, ...
(Date:8/1/2014)... Journal of Nutrition Education and Behavior (JNEB) announces the ... awards, which were presented at the Society for Nutrition ... Local to Global," in Milwaukee, Wisconsin, June 28 ... authors of the best article and best GEM published ... the JNEB Journal Committee and Board of Editors. ...
(Date:8/1/2014)... 1, 2014Biologists at The Scripps Research Institute (TSRI) have ... calorie-burning process in brown fat cells. , The ... Edition of the Proceedings of the National Academy ... as "brown fat thermogenesis," which is of great interest ... and may also protect against diabetes. , "This finding ...
Breaking Biology News(10 mins):Scripps Research Institute scientists find new calorie-burning switch in brown fat 2Scripps Research Institute scientists find new calorie-burning switch in brown fat 3
... Biosciences Institute (MBI) in the US have signed a ... Graduate Lecture Series. The lecture series consists of readable, ... nature and are inspired by annual programs at the ... The purpose of the MBI Graduate Lecture Series is ...
... A recent prospective, randomized, placebo-controlled clinical trial reports that ... a group of male veterans with epilepsy who were ... in Epilepsia , a journal of the International ... may help to prevent new vertebral fractures when taken ...
... from the Faculty of Medicine and the Faculty of ... old belief that eating chocolate is fattening. In an ... , the authors have shown that higher consumption of ... (fat deposited all over the body) and central fat ...
Cached Biology News:Calcium and vitamin D improve bone density in patients taking antiepileptic drugs 2Research shows that the more chocolate you eat, the lower your body fat level is 2
... RNAi Services offer you a full ... studies. B-Bridges advanced design parameters, effective ... ensure that you obtain quality results ... Design Service utilizes their proprietary B-Algo ...
... SNPs, Polymorphic uses proven, validated Sanger dideoxy ... analysis. We use high throughput capillary sequencing ... by sequencing in both directions. The use ... information, further confirming the location of the ...
... The Sub-Cell Model 96 and PowerPac basic power ... of nucleic acids in agarose gels. This Model ... x 10 cm UV-transparent gel tray with fluorescent ... power supply, 100-120 and 220-240 V, provides output ...
... mini ReadySub-Cell GT cell and PowerPac basic power ... of nucleic acids in agarose gels. The mini ... cables and electrodes, and leveling bubble. The PowerPac ... output of 10-300 V, 4-400 mA, and 75 ...
Biology Products: